Highlights

  • BrainChip (ASX:BRN) announced commercial availability of its Sequora edge AI processor IP in mid-October 2026.
  • Half-year revenue to 30 June 2026 rose 19% to US$1.22m, including US$0.61m in licence sales.
  • The net loss for the half was US$12.0m, with cash of US$20.3m at 30 June 2026.
  • AKD2500 development remains on schedule for an early December 2026 tape-out.

BrainChip Holdings (ASX:BRN) Ltd describes itself as pioneering the future of edge AI with neuromorphic computing, developing processors and intellectual property that run AI on low-power devices.113, down 2.17% in the current session.

Company Business

BrainChip develops the Akida family of neuromorphic processors, which are designed to process sensor data such as audio, vibration, radar and radio frequency signals directly on a device rather than in the cloud. The company earns revenue from three sources: licensing its processor IP to chip designers, selling physical chips and boards, and providing development services.

Its target markets include defence and government, industrial, automotive, consumer wearables and medical devices. BrainChip has operations in Australia and the United States, and its shares also trade in the US on the OTCQX market.

Recent Development

October 2026 brought two product announcements. In mid-October, BrainChip announced commercial availability of Sequora, a processor IP core aimed at running generative AI, including large language models, on battery-powered edge devices. The company said Sequora supports models up to about 3 billion parameters and uses a state-space design that keeps memory use fixed as data streams run longer. It is licensed as semiconductor IP that customers build into their own system-on-chip designs. BrainChip stated that customer engagement has begun but did not name customers or disclose licensing terms.

In late October, the company introduced the AKD1500 SPI, a co-processor that connects to microcontrollers through a standard SPI interface. It adds on-chip learning to products such as wearables, smart home devices and factory sensors, and is available through the BrainChip Shop, DigiKey or direct sales.

These followed the end-June announcement of commercial availability and initial production shipments of AKD1500 chips, made on GlobalFoundries' 22nm FD-SOI process. The company reported that several customers had received production-volume quantities for defence and wearable uses.

Financial Performance and Sector Context

For the half-year ended 30 June 2026, BrainChip reported revenue of US$1.22m, up 19% on the prior corresponding period. This comprised US$0.61m in licence sales, US$0.11m in product sales and US$0.50m from development services. Licence revenue came from Asia Pacific customers and included delivery of design assets to EDGEAI under an Akida 2.0 licence. BrainChip also signed an IP licence with ASICLAND and formed an ecosystem partnership with MicroIP. During the half, the company launched the Akida Radar Reference Platform and the AKD1500-powered Akida Communication Reference Platform for radio frequency signal classification. Two customers, one in the United States and one in Asia Pacific, each contributed more than 10% of revenue.

Total operating expenses rose 33% to US$13.6m, mainly due to research and development and headcount. The net loss was US$12.0m. Cash and cash equivalents were US$20.3m at 30 June 2026, and net cash used in operating activities was US$11.3m for the half. In the June quarter alone, net operating cash outflow was US$4.7m, down from US$5.3m in the March quarter, and customer receipts were US$0.15m. That report estimated a funding runway of about 4.4 quarters at the then-current operating burn.

Edge AI is a growing area of semiconductor design, with chip developers seeking lower power use and local processing. Revenue in this field often depends on design wins that take time to convert into royalties.

Risks to Consider

BrainChip (ASX:BRN) remains at an early commercial stage, and revenue is small relative to operating costs. The current cash balance and quarterly cash use mean funding needs are a key consideration. The LDA Capital put option agreement expired at the end of June 2026.

Manufacturing is another factor. The company said lower-than-expected yields mean the full AKD1500 production run of about 60,000 units is smaller than first planned, and it is investigating the cause. BrainChip has not disclosed quantified Sequora licensing revenue guidance.

What to Watch Next

The AKD2500 project is on schedule for an early December 2026 tape-out, according to the company. BrainChip has also flagged internal demonstrations of its generative AI platform in the remaining months of 2026 and expects Akida 2.0 commercialisation by 2027. Shareholders tracking ASX:BRN may look to the September quarter activity report for updated cash flow figures, customer receipts and any Sequora licensing progress. The company has also said four core AI models for radar and electronic warfare applications are in development. Commercial shipments of AKD1500 hardware platforms, including modules and development boards, are another item to follow.

Key Insights

BrainChip has moved from pre-production to commercial supply of AKD1500 chips during 2026 and has added Sequora IP and the AKD1500 SPI to its range. Licence revenue appeared in the first half after a nil prior corresponding period, although total revenue remains modest against a US$12.0m half-year loss. For ASX:BRN, converting product launches into licences, chip sales and royalties, while managing cash use, are the central issues.